Innovent Biologics, Inc. (HKEX: 01801) and Daiichi Sankyo Company (TSE: 4568) announced on August 9 that they have entered an exclusive agreement to commercialize Vanflyta (quizartinib) in China, an oral FLT3 inhibitor for a genetically defined, high-risk form of acute myeloid leukemia. Under the deal, Daiichi Sankyo keeps responsibility for developing, manufacturing, and supplying the drug, while Innovent takes sole commercialization rights in China and will lead market promotion there. For investors, this is a market-access deal layered on top of an already-approved product, not a new drug approval itself, and it adds a 20th commercialized product to Innovent’s China portfolio.

What Vanflyta Treats

Vanflyta was approved in China in June 2026 for adults with newly diagnosed acute myeloid leukemia, or AML, that tests positive for a FLT3-ITD mutation, for use alongside standard induction and consolidation chemotherapy and then as maintenance monotherapy afterward. That approval rests on results from the QuANTUM-First trial (NCT02668653), a study already used to support Vanflyta’s approvals in the United States, Europe, and Japan; the release does not restate the trial’s efficacy figures here, so readers should treat the approval itself, rather than any specific survival or response number, as the verified fact.

Why the FLT3-ITD Mutation Matters

AML is an aggressive blood cancer, and FLT3 mutations, found in roughly a quarter of all AML cases, are the most common genetic mutation identified in the disease. About 80% of those FLT3 mutations are the ITD subtype, which the release describes as driving faster cancer growth and a meaningfully worse prognosis, including a higher risk of relapse and shorter overall survival, compared with AML without the mutation. Vanflyta is designed specifically to target that FLT3-ITD mutation, which is why an accurate genetic test is required before the drug is used.

The Scale of the Market

China carries a meaningful share of the global disease burden this deal is aimed at. The companies cite figures showing more than 487,000 new leukemia cases and over 305,000 deaths worldwide in 2022, with AML making up close to a quarter of leukemia cases globally and about half of leukemia cases in China specifically; China alone recorded roughly 82,000 new leukemia diagnoses and more than 50,000 deaths from the disease in 2022, making it the country’s tenth-deadliest cancer by that count. Those figures come from cancer-registry and public health sources cited in the release rather than being independently verified here, but they illustrate why a populous market like China matters for a drug aimed at this specific mutation.

What the Companies Are Saying

Innovent Chief Commercial Officer Vivian Zhang described the deal as an important milestone for the company’s hematology franchise, noting that Vanflyta joins an existing oncology portfolio that includes Tyvyt, Halpryza, olverembatinib, Fucaso, and Jaypirca. Daiichi Sankyo’s China President, Michio Hayashi, said the companies expect the partnership to help expand patient access to Vanflyta and, in his words, help improve outcomes for this high-risk patient population. Both statements are the companies’ own characterizations of the deal’s expected benefit rather than a verified clinical or commercial outcome.

What Wasn’t Disclosed

Neither company disclosed the deal’s financial terms in the release, including any upfront payment, milestone payments, or royalty structure Innovent might owe Daiichi Sankyo, or how revenue from Vanflyta sales in China would be split between the two companies. That is a meaningful gap for investors trying to size the deal’s financial impact, and none of those figures are estimated here.

How This Fits Innovent’s Business Model

The agreement fits a broader pattern in Innovent’s business model: rather than developing every drug in its portfolio internally, the company has built a network of more than 30 partnerships with global pharmaceutical companies, including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and LG Chem, licensing in products it can commercialize through its China sales infrastructure. Innovent says it currently has one asset under review with China’s National Medical Products Administration, five in Phase 3 or pivotal trials, and 14 more in earlier clinical stages, alongside the 20 products it has already launched. This Vanflyta deal is an extension of that same commercialization-partner strategy rather than a new type of transaction for the company.

What’s Next

For Daiichi Sankyo, the arrangement lets the company retain the more capital-intensive manufacturing and development responsibilities for Vanflyta in China while leaning on a local partner with established commercial reach, a structure common among multinational drugmakers entering or expanding in the Chinese market rather than building out their own sales force there. Daiichi Sankyo describes its own strategic focus as oncology, built around what it calls an industry-leading antibody-drug conjugate portfolio, of which Vanflyta, a small-molecule FLT3 inhibitor rather than an antibody-drug conjugate, is a complementary rather than core asset. Both companies’ releases include standard forward-looking-statement disclaimers noting that actual results could differ from any expectations expressed about the partnership’s benefits. This article covers a commercialization agreement for an already-approved therapy and is not an investment recommendation.

Sources

• Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China, PRNewswire, August 9, 2026.

Editorial Disclosure

This article is based on a press release issued jointly by Innovent Biologics, Inc. and Daiichi Sankyo Company on August 9, 2026, distributed via PRNewswire. Innovent Biologics trades on the Hong Kong Stock Exchange under the ticker 01801; Daiichi Sankyo trades on the Tokyo Stock Exchange under the ticker 4568. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the anticipated benefits of the commercialization agreement are forward-looking and involve risks and uncertainties; financial terms of the agreement were not disclosed. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.